INO
TIP
Re: INO
Ik probeer niet te veel meer aan daytrading te doen. Ik blijf wel geïnteresseerd de beurs volgen. Het is nogal frustrerend dat je op 1 dag meer kan verdienen dan jaren interest.
Ik speel maar met een beperkt bedrag op de beurs. Ik zou mijn winst op Cardio 3 kunnen nemen en in Amerikaans farma gaan. Ik wordt de laatste jaren echter meer en meer chauvinistisch in mijn geldkeuzes...
Ik speel maar met een beperkt bedrag op de beurs. Ik zou mijn winst op Cardio 3 kunnen nemen en in Amerikaans farma gaan. Ik wordt de laatste jaren echter meer en meer chauvinistisch in mijn geldkeuzes...
Re: INO
dan zou ik dat geld alvast van de tafel halen Stier ! en wacht geduldig af wat er komen zal qua biotechs op de Amerikaanse beurzen.
Kijk effe -samen met mij- naar wat TTPH doet vandaag. Ik verwacht een stijging maar zeker is men .... nooit ...
Kijk effe -samen met mij- naar wat TTPH doet vandaag. Ik verwacht een stijging maar zeker is men .... nooit ...
Re: INO
INO terug aan 2 USD.
Re: INO
je hebt maw goed geslapen?
je gaat er nog meer plezier aan beleven hoor!
de shorts hadden gisteren een heel slechte dag en vandaag is het vrijdag dus die moeten coveren als ze dat gisteren nog niet gedaan hebben; have fun!
je gaat er nog meer plezier aan beleven hoor!
de shorts hadden gisteren een heel slechte dag en vandaag is het vrijdag dus die moeten coveren als ze dat gisteren nog niet gedaan hebben; have fun!
I don't drink. You know, the routine grind drives me to drink. Tragedy, I take straight.
Re: INO
Mijn aandeel in INO is niet zo groot hoor. Ik laat nooit mijn slaap voor pharma. De ene dag is de andere niet.
http://finance.yahoo.com/news/inovio-ph ... 00426.html" onclick="window.open(this.href);return false;
INO is heel goed bezig en heeft een uniek profiel, ze kunnen met baanbrekende resultaten op de proppen komen.
Ablynx is misschien een beetje een Belgische tegenhanger. Beiden werken op een unieke manier aan geneesmiddelen. Ook in Ablynx volle vertrouwen.
http://finance.yahoo.com/news/inovio-ph ... 00426.html" onclick="window.open(this.href);return false;
INO is heel goed bezig en heeft een uniek profiel, ze kunnen met baanbrekende resultaten op de proppen komen.
Ablynx is misschien een beetje een Belgische tegenhanger. Beiden werken op een unieke manier aan geneesmiddelen. Ook in Ablynx volle vertrouwen.
Re: INO
Leuk INO nieuws, vers van de pers:
Inovio Pharmaceutical’s DNA Vaccine for the Deadly MERS Virus Induces Robust Immune Response in Preclinical Trial
No vaccine exists for the MERS virus that has killed 42% of those infected
BLUE BELL, Pa., Nov. 20, 2013 -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that preclinical testing of a DNA synthetic vaccine for the virulent Middle East Respiratory Syndrome coronavirus (MERS) induced robust and durable immune responses, demonstrating the potential for a SynCon® DNA vaccine to prevent and treat this deadly virus.
Since 2012, when the virus was first identified, 153 cases from nine Middle Eastern countries have been reported and, alarmingly, 42% of these cases have been fatal. MERS is similar to the SARS virus which infected 8,000 people several years ago. MERS differs from SARS in that it appears to be less contagious, but MERS is almost five times as fatal as SARS, which killed 10% of those infected. There is no vaccine or effective treatment for MERS.
In this study, DNA vaccine constructs targeting multiple MERS antigens were generated using Inovio's SynCon® vaccine platform. These SynCon constructs were administered via Inovio's CELLECTRA® electroporation-based delivery technology. The vaccine constructs were observed to induce strong neutralizing antibodies and broad CD8+ T cells in mice. These findings are vital given the importance of neutralizing antibodies in preventing infection and the role T cells play in clearing infection by killing cells that harbor the virus.
Dr. J. Joseph Kim, Inovio's President and CEO, said, "Our SynCon® platform has again generated a synthetic vaccine candidate that shows promise for providing a treatment where there is none. With human data showing the powerful killing effect of T cells generated by our vaccine for HIV and our therapy for HPV-associated cervical dysplasia and various cancers, we look forward to providing Inovio's answer to MERS, a deadly infectious disease that has unknown pandemic potential. What’s even more impressive about our candidate vaccine is that it is designed with the goal to universally protect against multiple strains of MERS, which has been shown to have diverse genetic variants. With appropriate external funding, this product could become an effective shield against this deadly virus."
To begin the study, a consensus MERS “spike” protein vaccine construct was created based on multiple strains of the MERS virus. Inovio’s MERS DNA vaccine was immunogenic in mice and seroconversion, or the development of detectable specific antibodies in the blood as a result of immunization, was observed in all animals. Furthermore, the antibodies generated by the vaccine in 100% of mice (20 of 20) were able to neutralize or completely block actual infection of MERS virus in the cells, demonstrating the protective potential of this vaccine. In contrast, none of the unvaccinated mice in the control group (10) generated neutralizing antibodies.
Researchers also observed that vaccination was highly T-cell immunogenic, generating robust and broad T cell responses as extensively analyzed by the standardized T cell ELISPOT assay. The vaccine produced robust CD8+ and CD4+ T cell responses against multiple epitopes of the MERS spike protein. This increased diversity and magnitude of cellular responses may be critical for effectively mitigating MERS infection.
About MERS
Middle East Respiratory Syndrome (MERS) is a viral respiratory illness first reported in Saudi Arabia in 2012. MERS appears to have been transmitted from an "animal reservoir" to humans but human to human transmission has also been confirmed. The virus has not been shown to spread in a sustained way in communities, but the situation is still evolving. Like SARS, which infected 8,000 people and was fatal in nearly 10% of cases, MERS appears to cause a severe lung infection. MERS differs in that it also causes rapid kidney failure and its extremely high death rate has caused serious concern among global health officials.
The World Health Organization has confirmed 153 cases of MERS in nine countries; 64, or 42%, of these cases have been fatal. All cases have been directly or indirectly linked through travel to or residence in four countries: Saudi Arabia, Qatar, Jordan, and the United Arab Emirates. Experts are still struggling to understand MERS, for which there is no vaccine. No cases have been reported in the U.S., but as a precaution, the CDC has prepared diagnostic kits that have been distributed throughout the U.S.
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis. Partners and collaborators include Roche, the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at http://www.inovio.com" onclick="window.open(this.href);return false;.
CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101 bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com
Inovio Pharmaceutical’s DNA Vaccine for the Deadly MERS Virus Induces Robust Immune Response in Preclinical Trial
No vaccine exists for the MERS virus that has killed 42% of those infected
BLUE BELL, Pa., Nov. 20, 2013 -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that preclinical testing of a DNA synthetic vaccine for the virulent Middle East Respiratory Syndrome coronavirus (MERS) induced robust and durable immune responses, demonstrating the potential for a SynCon® DNA vaccine to prevent and treat this deadly virus.
Since 2012, when the virus was first identified, 153 cases from nine Middle Eastern countries have been reported and, alarmingly, 42% of these cases have been fatal. MERS is similar to the SARS virus which infected 8,000 people several years ago. MERS differs from SARS in that it appears to be less contagious, but MERS is almost five times as fatal as SARS, which killed 10% of those infected. There is no vaccine or effective treatment for MERS.
In this study, DNA vaccine constructs targeting multiple MERS antigens were generated using Inovio's SynCon® vaccine platform. These SynCon constructs were administered via Inovio's CELLECTRA® electroporation-based delivery technology. The vaccine constructs were observed to induce strong neutralizing antibodies and broad CD8+ T cells in mice. These findings are vital given the importance of neutralizing antibodies in preventing infection and the role T cells play in clearing infection by killing cells that harbor the virus.
Dr. J. Joseph Kim, Inovio's President and CEO, said, "Our SynCon® platform has again generated a synthetic vaccine candidate that shows promise for providing a treatment where there is none. With human data showing the powerful killing effect of T cells generated by our vaccine for HIV and our therapy for HPV-associated cervical dysplasia and various cancers, we look forward to providing Inovio's answer to MERS, a deadly infectious disease that has unknown pandemic potential. What’s even more impressive about our candidate vaccine is that it is designed with the goal to universally protect against multiple strains of MERS, which has been shown to have diverse genetic variants. With appropriate external funding, this product could become an effective shield against this deadly virus."
To begin the study, a consensus MERS “spike” protein vaccine construct was created based on multiple strains of the MERS virus. Inovio’s MERS DNA vaccine was immunogenic in mice and seroconversion, or the development of detectable specific antibodies in the blood as a result of immunization, was observed in all animals. Furthermore, the antibodies generated by the vaccine in 100% of mice (20 of 20) were able to neutralize or completely block actual infection of MERS virus in the cells, demonstrating the protective potential of this vaccine. In contrast, none of the unvaccinated mice in the control group (10) generated neutralizing antibodies.
Researchers also observed that vaccination was highly T-cell immunogenic, generating robust and broad T cell responses as extensively analyzed by the standardized T cell ELISPOT assay. The vaccine produced robust CD8+ and CD4+ T cell responses against multiple epitopes of the MERS spike protein. This increased diversity and magnitude of cellular responses may be critical for effectively mitigating MERS infection.
About MERS
Middle East Respiratory Syndrome (MERS) is a viral respiratory illness first reported in Saudi Arabia in 2012. MERS appears to have been transmitted from an "animal reservoir" to humans but human to human transmission has also been confirmed. The virus has not been shown to spread in a sustained way in communities, but the situation is still evolving. Like SARS, which infected 8,000 people and was fatal in nearly 10% of cases, MERS appears to cause a severe lung infection. MERS differs in that it also causes rapid kidney failure and its extremely high death rate has caused serious concern among global health officials.
The World Health Organization has confirmed 153 cases of MERS in nine countries; 64, or 42%, of these cases have been fatal. All cases have been directly or indirectly linked through travel to or residence in four countries: Saudi Arabia, Qatar, Jordan, and the United Arab Emirates. Experts are still struggling to understand MERS, for which there is no vaccine. No cases have been reported in the U.S., but as a precaution, the CDC has prepared diagnostic kits that have been distributed throughout the U.S.
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis. Partners and collaborators include Roche, the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at http://www.inovio.com" onclick="window.open(this.href);return false;.
CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101 bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com
Re: INO
ik heb pre-market mijn aandelen verkocht : $2.21 !
config zie je nu hoe snel het kan gaan (de goede kant op dan )... niet panikeren zoals ik al zei. STALEN zenuwen ok ?
Soms mis ik de boot ook hoor, zoals ik bij NWBO gedaan heb, maar nu dat ik INO geïnd heb, zal ik daar wellicht terug in investeren als de offering concreet gemaakt wordt tenminste.
config zie je nu hoe snel het kan gaan (de goede kant op dan )... niet panikeren zoals ik al zei. STALEN zenuwen ok ?
Soms mis ik de boot ook hoor, zoals ik bij NWBO gedaan heb, maar nu dat ik INO geïnd heb, zal ik daar wellicht terug in investeren als de offering concreet gemaakt wordt tenminste.
Laatst gewijzigd door insider op 20 november 2013, 14:36, 1 keer totaal gewijzigd.
I don't drink. You know, the routine grind drives me to drink. Tragedy, I take straight.
Re: INO
Waarom niet meer in portefeuille?
Re: INO
omdat ik er dik aan verdiend heb en ik de spreuk "wie het onderste uit de kan wil krijgt ..." indachtig ben !Config85 schreef:Waarom niet meer in portefeuille?
trouwens niets belet mij van terug in INO te stappen eens de hype voorbij is ... als ze nog voorbij gaat tenminste !
Laatst gewijzigd door insider op 20 november 2013, 14:40, 1 keer totaal gewijzigd.
I don't drink. You know, the routine grind drives me to drink. Tragedy, I take straight.
Re: INO
Ik blijf rustig zitten... nog teveel opwaarts potentieel aan die koersen.
We'll see.
We'll see.
Re: INO
natuurlijk : ik verplicht niemand tot iets maar voor mij was het voldoende ... was de zwaarste positie in mijn portefeuille ...Config85 schreef:Ik blijf rustig zitten... nog teveel opwaarts potentieel aan die koersen.
We'll see.
But .... don't fall in love with your stock !
I don't drink. You know, the routine grind drives me to drink. Tragedy, I take straight.
Re: INO
@ evita : wat denk je met ion? heb je ze nog altijd in portefeuille? ik wel , maar het is nogal stil vind ik??
Re: INO
Ja, ik heb ze nog altijd en wacht hoopvol (!) af !
Re: INO
idem hier .
hoop is een goed ontbijt maar een slecht avondmaal,...
hoop is een goed ontbijt maar een slecht avondmaal,...
Re: INO
gene paniek .... dat komt goed maar eindejaarsperiode is nooit vet qua stijgingen van koersen ...
I don't drink. You know, the routine grind drives me to drink. Tragedy, I take straight.